Latest news

07/2023: Immunochemotherapy for Waldenström's disease | Ulm University Hospital (uniklinik-ulm.de)

12/2022: Mission against Waldenström's disease | Ulm University Hospital (uniklinik-ulm.de)

06/2022: Congratulations to Tobias Ammer, Shiva Bamezai and Andrew Muranyi on the acceptance of their paper titled: Npm1 Haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice. Congratulations! Further information can be found at: https://pubmed.ncbi.nlm.nih.gov/35468619/

05/2022: We welcome PhD student Dominique Desef to our team

05/2022: The Follicular Lymphoma Registry reaches 600 enrolled patients!

03/2022: We welcome post-doc Palash Maity to our team

03/2021: POLE-1 initiated.

03/2021: The 300th patient in the FL registry was enrolled.

01/2021: CZAR-1 initiated (in Germany).

05/2020: National Follicular Lymphoma Registry opened!
The national registry for follicular lymphoma has now been opened in Ulm. All patients with follicular lymphoma can be included in the registry. The only requirement is a reference pathology to confirm the diagnosis. For more information, please contact lymphom.register@uniklinik-ulm.de or fl.register@uniklinik-ulm.de

04/2020: Marginal zone register reaches 500 included patients!
The national MZL registry, which is funded by German Cancer Aid, has now enrolled its 500th patient. Thank you for your support! Information at: mzol.register@uniklinik-ulm.de

02/2020: ECWM-2 study actively recruiting!
The ECWM-2 study for patients with previously untreated Waldenström's disease has been opened at several centres in Germany. It is a single-arm phase II trial offering a highly effective chemotherapy-free combination of rituximab/ibrutinib and bortezomib SC to patients in need of treatment. Information at studien.gla@uniklinik-ulm.de

01/2020: OLYMP-1 and COUP-1 trial for patients with marginal zone lymphoma active!
The OLYMP-1 and COUP-1 trials are aimed at patients with marginal zone lymphoma in need of treatment who are treatment-naive (OLYMP-1) or treatment-naive or relapsed (COUP-1). They both offer chemotherapy-free treatments, offering the anti-CD20 antibody obinutuzumab as monotherapy in the OLYMP-1 trial or the PI3K inhibitor copanlisib in combination with rituximab in the COUP-1 trial. Information at studien.gla@uniklinik-ulm.de

11/2019: Prof Buske is appointed President of the German Lymphoma Alliance e.V. (GLA)

11/2018: Congratulations to Lisa Marie Kaiser (B.Sc.) on her study success! https://www.uniklinik-ulm.de/aktuelles/detailansicht/news/dhbw-heidenheim-verabschiedet-651-bachelor-absolventinnen-und-absolventen.html

02/2018: Congratulations to Tamoghna Mandal for his publication on the use of nanoparticles for the targeted therapy of AML stem cells.

01/2018: A happy and successful new year to all!

11/2017: Very successful organisation of the first annual study meeting of the GLA in Ulm with over 200 participants: we thank all participants for their great support!

09/2017: We welcome our new employees: Abdul-Habib Rahimi and Tobias Ammer as PhD students - we wish you a good start!

10/2017: We welcome three PhD students from China: Xinying Li, Quingyu Xu and Xiaoran Zheng!

07/2017: The "Research Unit, FOR 2675", together with our project "Aging and clonal heamtopoiesis" was positively evaluated by the DFG and will initially be funded for 3 years

05/2017: Our new "Peptide-SFB" was positively evaluated by the DFG and will initially be funded for 4 years by the DFG. ! The project is coordinated by Prof Dr Frank Kirchhoff (spokesperson), Prof Dr Martin Plenio and Prof Dr Christian Buske (deputy spokespersons).

03/2017: The GLA (German Lymphoma Alliance) was successfully founded in Frankfurt, a great and very important day for clinical and translational lymphoma research in Germany! We were delighted to organise the founding meeting for the GLA.

02/2017: Congratulations to Prof Dr Michaela Feuring-Buske for being awarded the title of "Professor"!

02/2017: We welcome our new technical assistants Julia Müller and Burcu Demir

12/2016: Eva Gentner (PhD student) and Julia Rappold (TA) are leaving our institute - congratulations to Eva on her successful doctorate and we wish you both every success for the future!

11/2016: Congratulations to Deidre Daria on successfully completing her PhD!

11/2016: We congratulate Michaela Feuring-Buske, Eva Gentner and Vijay Rawat on the publication of their work on the significance of the VENTX gene in AML patients in the journal "Oncotarget".

10/2016: We wish Dr Kristine Höfer a good start with us. She will support the "Clinical Trials" team.

10/2016: We welcome our new colleague Ms Dagmar Eiermann to our Clinical Trials team.

10/2016: We are delighted that the work on a leukaemia stem cell signature in patients with AML has been accepted in the journal "Nature"! We participated in this work under the leadership of John Dick's team from Toronto, Canada.

10/2016: Congratulations to all accepted papers at the upcoming ASH 2016 in San Diego. The institute is represented with 6 contributions, 3 of which are talks!

09/2016: We say goodbye to our long-standing and valued colleague Anna Kechter and wish her all the best for the future!

06/2016: Congratulations to Naidu Vegi for his work on AML1-ETO positive leukaemia, which has been accepted for publication in 'Cell Reports'.

05/2016: Second funding period of the SFB 1074 approved, in which the Institute is involved with three subprojects!

04/2016: We welcome Juliane Brocke as a new member of staff! She will strengthen our "Clinical Studies" team.

04/2016: new ESMO guidelines on acute lymphoblastic leukaemia ALL published.

03/2016: We wish Monja Claus a good start with us. She will support the secretariat.

03/2016: we congratulate Deidre Daria and Nicole Kirsten on the publication of their work on the significance of the GPR56 gene in AML in "Leukemia".

09/2015: new ESMO guidelines on CLL published.